NCT05810740View on ClinicalTrials.gov

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 22, 2022

Study Completion Date

January 18, 2023

Conditions

MelanomaBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma

Interventions

DRUG

Binimetinib 15 MG

Binimetinib 15 mg tablet

DRUG

Binimetinib 45 MG

Binimetinib 45 mg tablet

Trial Locations (1)

35000

Biotrial, Rennes

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biotrial

INDUSTRY

lead

Pierre Fabre Medicament

INDUSTRY

NCT05810740 - Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | Biotech Hunter | Biotech Hunter